IN8bio, Inc.
INAB
$0.1449
$0.01219.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.96% | -6.46% | -8.57% | -2.39% | -2.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.40% | -3.48% | 2.51% | 5.41% | 4.06% |
| Operating Income | 15.40% | 3.48% | -2.51% | -5.41% | -4.06% |
| Income Before Tax | 11.66% | -1.43% | -5.52% | -5.00% | -3.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.66% | -1.43% | -5.52% | -5.00% | -3.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.66% | -1.43% | -5.52% | -5.00% | -3.82% |
| EBIT | 15.40% | 3.48% | -2.51% | -5.41% | -4.06% |
| EBITDA | 16.50% | 3.71% | -1.87% | -3.68% | -0.87% |
| EPS Basic | 46.77% | 39.47% | 32.32% | 32.30% | 31.92% |
| Normalized Basic EPS | 49.22% | 42.43% | 35.11% | 33.04% | 32.60% |
| EPS Diluted | 46.52% | 39.26% | 32.13% | 32.13% | 31.76% |
| Normalized Diluted EPS | 49.22% | 42.43% | 35.11% | 33.04% | 32.60% |
| Average Basic Shares Outstanding | 83.45% | 78.29% | 55.87% | 55.50% | 53.65% |
| Average Diluted Shares Outstanding | 83.45% | 78.29% | 55.87% | 55.50% | 53.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |